东诚药业股价跌1.03%，兴业基金旗下1只基金重仓，持有123.49万股浮亏损失17.29万元

Group 1 - Dongcheng Pharmaceutical's stock price decreased by 1.03% to 13.49 yuan per share, with a total market capitalization of 11.12 billion yuan as of the report date [1] - The company, established on December 31, 1998, specializes in the research, production, and sales of heparin sodium raw materials and chondroitin sulfate, with revenue composition as follows: 44.16% from raw materials, 36.38% from nuclear medicine products, 13.17% from formulations, and 6.30% from other sources [1] Group 2 - Xinyi Fund holds a significant position in Dongcheng Pharmaceutical, with its fund "Xinyi Healthcare A" owning 1.2349 million shares, representing 4.65% of the fund's net value, making it the sixth-largest holding [2] - The fund has a total scale of 261 million yuan and has achieved a year-to-date return of 22.12%, ranking 4110 out of 8087 in its category [2] Group 3 - The fund manager of Xinyi Healthcare A is Chen Xu, who has been in the position for nearly 5 years, with the fund's total assets amounting to 404 million yuan [3] - During Chen Xu's tenure, the best fund return was -20.35%, while the worst return was -22.24% [3]